Diploma (LON:DPLM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Berenberg Bank in a research report issued on Wednesday,Digital Look reports. They presently have a GBX 6,350 target price on the stock. Berenberg Bank’s price objective points to a potential upside of 21.88% from the stock’s current price.
A number of other brokerages have also weighed in on DPLM. Peel Hunt reaffirmed a “buy” rating and set a GBX 6,150 target price on shares of Diploma in a research report on Tuesday. Jefferies Financial Group raised their price objective on shares of Diploma from GBX 4,500 to GBX 5,200 and gave the company a “hold” rating in a research note on Thursday, September 11th. JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 4,440 target price on shares of Diploma in a report on Wednesday, August 6th. Finally, Royal Bank Of Canada upgraded Diploma to an “outperform” rating and lifted their price target for the company from GBX 4,500 to GBX 6,000 in a research note on Friday, October 3rd. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Diploma has a consensus rating of “Moderate Buy” and a consensus price target of GBX 5,605.71.
View Our Latest Stock Report on Diploma
Diploma Stock Down 1.5%
Insider Buying and Selling
In other Diploma news, insider Geraldine Huse bought 750 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The stock was purchased at an average cost of GBX 3,997 per share, with a total value of £29,977.50. Company insiders own 1.13% of the company’s stock.
About Diploma
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Articles
- Five stocks we like better than Diploma
- What is a Microcap Stock? Everything You Need to Know
- Down 45% Year-to-Date, Novo Nordisk Ignites a Price War
- How to Buy Gold Stock and Invest in Gold
- Institutions Love These 3 Companies, Should You As Well?
- 3 Tickers Leading a Meme Stock Revival
- 3 Data Center Stocks Are Soaring—Analysts Think 1 Could Go Higher
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.
